Uddin's Comments on Buy rating
For the 27 subjects in TLTs pivotal trial to achieve the same CR rate at 360 days as Keytruda, an additional three subjects out of the 11 which had not received both doses of TLD-1433 would need to achieve CR representing a 27 per cent threshold (3/11) we believe this is a feasible threshold for Theralase given the data presented to date, Uddin said... As the Phase 2 pivotal trial continues to progress, we believe the results should elucidate the efficacy potential of TLT-1433. We are maintaining our SPECULATIVE BUY rating and a target price of $0.70, Uddin wrote.